Anastasios Pandraklakis
Overview
Explore the profile of Anastasios Pandraklakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
33
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pandraklakis A, Liakou C, La Russa M, Ochoa-Ferraro R, Stearns A, Burbos N
Gynecol Oncol Rep
. 2024 Nov;
56:101536.
PMID: 39524471
Objective: The aim of this study is to evaluate the implementation of the elements of enhanced recovery (ERAS) protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for...
2.
Comparing oncological outcomes of robotic versus open surgery in the treatment of endometrial cancer
Nikolopoulos M, Pickering M, Thu K, Mitsopoulos V, Pandraklakis A, Lippiatt J, et al.
Arch Gynecol Obstet
. 2024 Sep;
310(5):2631-2637.
PMID: 39230794
Purpose: Robotic surgery has been incorporated in the treatment of endometrial cancer, with evidence suggesting that minimal access surgery offers advantages over laparotomy including less blood loss, lower rate of...
3.
Liakou C, Pandraklakis A, LA Russa M, Turnbull H, Nieto J, Duncan T, et al.
Anticancer Res
. 2023 Sep;
43(10):4593-4599.
PMID: 37772571
Background/aim: Emerging data suggest that addition of hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of interval cytoreduction for patients with metastatic ovarian cancer is associated with a survival benefit. However,...
4.
Pandraklakis A, Haidopoulos D, Lappas T, Stamatakis E, Valsamidis D, Oikonomou M, et al.
Int J Gynecol Cancer
. 2023 Aug;
33(11):1794-1799.
PMID: 37652530
Objective: To evaluate the safety and the effectiveness of thoracic epidural analgesia as part of the enhanced recovery after surgery (ERAS) multimodal analgesic protocol in patients with gynecologic oncology who...
5.
Pandraklakis A, Haidopoulos D, Lappas T, Stamatakis E, Oikonomou M, Valsamidis D, et al.
Cureus
. 2023 Jul;
15(6):e40453.
PMID: 37456369
Objective The aim of this study is to present our experience and evaluate the safety and outcomes of the implementation of Enhanced Recovery After Surgery (ERAS) protocols in obese patients...
6.
Pandraklakis A, Mitsopoulos V, Biliatis I
Gynecol Oncol Rep
. 2023 Apr;
47:101170.
PMID: 37091213
The standard treatment of advanced ovarian, fallopian tube and peritoneal cancer is cytoreductive surgery followed by platinum-based chemotherapy (du Bois et al., 2005). This type of cancer expands through the...
7.
Pandraklakis A, Prodromidou A, Haidopoulos D, Paspala A, Oikonomou M, Machairiotis N, et al.
Cureus
. 2022 Aug;
14(6):e26222.
PMID: 35911338
The presence of ascites is a common clinical presentation in gynecologic oncology patients. Hemorrhagic ascites (HA) due to endometriosis is a rare presentation that can be easily misdiagnosed as ovarian...
8.
Thomakos N, Dimopoulou S, Sotiropoulou M, Machairiotis N, Pandraklakis A, Haidopoulos D, et al.
Horm Mol Biol Clin Investig
. 2021 Mar;
42(1):105-111.
PMID: 33781006
The aim of this study is to evaluate and compare outcomes of patients with mixed and pure endometrial carcinomas (MEC). We reviewed data of patients with MEC, endometroid (EC), serous...
9.
Prodromidou A, Pandraklakis A, Rodolakis A, Thomakos N
Diagnostics (Basel)
. 2020 Dec;
11(1).
PMID: 33375037
Endometriosis is a common benign gynecological condition defined as the presence of endometrial tissue in tissues outside the uterine cavity. Apart from the common sites of endometriosis, rare sites other...
10.
Pandraklakis A, Thomakos N, Prodromidou A, Oikonomou M, Papanikolaou I, Vlachos D, et al.
Folia Med (Plovdiv)
. 2020 Oct;
62(3):453-461.
PMID: 33009739
Advances in modern medicine have allowed patients with early stage cervical cancer (stages Ia - IIai) to preserve their fertility with oncologic efficacy comparable to previous radical treatments. A variety...